Elena E. Perez, M.D., Ph.D.
Dr. Perez completed her residency training in Pediatrics and fellowship in Allergy and Immunology at the Children’s Hospital of Philadelphia from 1998-2004. She then served on the faculty at the University of Pennsylvania until 2009, when she relocated to All Children’s Hospital and USF in St. Petersburg. While in Philadelphia, Dr. Perez served as Assistant Professor of Pediatrics and worked in collaboration with Sangamo Biosciences in translational research, applying zinc finger nuclease technology for the modification of the CCR5 gene, a major co-receptor of HIV, under the mentorship of Carl June, MD. Dr. Perez joined the faculty of the Division of Allergy and Immunology, where she will maintain an active research laboratory in T cell biology, HIV, and primary immunodeficiency diseases and care for patients with primary immunodeficiency.
Education & Training
| B.S. | University of Florida, 1991 |
| M.D. & Ph.D. | University of Florida, 1998 |
| Pediatric Residency | The Children’s Hospital of Philadelphia, 1998-2001 |
| Allergy/Immunology Fellowship | The Children’s Hospital of Philadelphia, 2001-2004 |
Board Certifications
- American Board of Pediatrics
- American Board of Allergy and Immunology
Selected Publications
Perez EE., Rose SL., Peyser B., Lamers SL., Burkhardt B., Dunn BM., Hutson AD., Sleasman JW., Goodenow MM.: Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. Journal of Infectious Diseases 183(4): 579-88, Feb 15 2001.
Perez, EE., and Sulivan, KE., Chromosome 22q11.2 Deletion Syndrome (DiGeroge Syndrome/Velocardiofacial Syndrome). Curret Opin Pediatrics. 2002 Dec; 14(6): 678-83
Perez EE., Bokszczanin A., McDonald-McGinn D., Zackai EH., Sullivan KE.: Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 112(4): e325, Oct 2003.
Perez, EE., Riley JL., Carroll RG., von Laer D., June CH.: Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clinical Immunology 115(1): 26-32, Apr 2005.
Heltzer, ML, Paessler, M., Raffini, L., Bunin, N., and Perez, EE. Successful haploidentical bone marrow transplant in reticular dysgenesis: three year follow-up. Journal of Allergy and Clinical Immunology. 2007 Oct;120(4):950-2. Epub 2007 Sep 12
Perez, EE., Jouvenot, T., Wang, J., Miller, JC., Kim, K., Liu, O., Wang, N., Lee, G., Bartesevic, V., Lee, Y., Guschin, D., Rupniewski, I., Waite, A., Carpenito, C., Carroll, R., Orange, J., Urnov, F., Rebar, E., Ando, D., Gregory, P., Riley, J., Holmes, M., and Carl H. June. Establishment of Permanent HIV-1 Resistance in CD4 T-cells by Genome Editing. Nature Biotechnology. 2008 June; (26)7: 808-816.
Varela-Rohena,A., Carpenito,C., Perez,E.E., Richardson,M., Parry,R.V., Milone,M., Scholler,J., Hao,X.,Mexas,A., Carroll,R.G., June,C.H., and Riley,J.L. 2008. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res Oct 8 [Epub ahead of print].
